Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population
- 1 October 2017
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 147 (1) , 36-40
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003–2008: The Effect of the NCI Clinical RecommendationFrontiers in Oncology, 2014
- Disparities in Ovarian Cancer Care Quality and Survival According to Race and Socioeconomic StatusJNCI: Journal of the National Cancer Institute, 2013
- Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer2011
- The impact of comorbidity and stage on ovarian cancer mortality: A nationwide Danish cohort studyBMC Cancer, 2008
- Intraperitoneal chemotherapy in the first‐line treatment of women with stage III epithelial ovarian cancerCancer, 2007
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group StudyGynecologic Oncology, 2006
- How to measure comorbiditya critical review of available methodsJournal of Clinical Epidemiology, 2003
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Partial residuals for the proportional hazards regression modelBiometrika, 1982